Compare Hormel Foods Corp (HRL) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Hormel Foods Corp trades at $20.03 (market cap $10.57B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Hormel Foods Corp is far larger — about 10.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Hormel Foods Corp pays a 6.09% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HRL | MRVI | |
|---|---|---|
Market Cap | $10.57B | $972.90M |
Volume | 4,381,202 | 4,325,710 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $9.00 |
52-Week Low | $19.19 | $2.83 |
Typical Hold Time | 99 Days | 0 Days |
Enterprise Value | $12.56B | $1.08B |
Dividend Yield | 6.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.81, up 2.64% today, with a mixed technical outlook showing bearish moving averages but oversold RSI signals. The company reported Q2 2026 EPS of $0.37, beating estimates, but net income margin has declined to 2.82% in 2026 from 6.75% in 2024. Recent news highlights the $1.06 billion Brakebush acquisition to expand its chicken business, while the dividend yield remains a key attraction with 60 consecutive years of increases.
The stock offers a compelling dividend history but faces growth challenges with shrinking profit margins and elevated P/E of 30.98. Analyst consensus is cautious with a $25 price target, and the acquisition integration poses execution risk. Upside depends on successful cost management and foodservice expansion, while margin pressure and high payout ratios remain headwinds.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
